bg content top pipeline

Molecules Currently in Development and a Licenseable Delivery Vehicle

The Pipeline

RDD01 Pipeline-Chart 280217

RDD is initiating a Phase 3 study for treatment of chronic anal fissure with RDD 1219, with a novel sustained release drug-delivery device — the Capository™. This product has numerous competitive advantages over the one marketed product for this indication. The anal fissure market is anticipated to reach $5-600M.

RDD recently completed a successful Phase 2a study of RDD 0315 in fecal incontinence, which reached the primary endpoint (lowered frequency of incontinence events). There are no approved therapies for this indication. Fecal incontinence market has the potential to approach $3B in sales.

Pipeline-icon

Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).

 

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2017, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top